JMP Securities Sticks to Their Buy Rating for Savara Inc (SVRA)

In a report issued on February 7, Liisa Bayko from JMP Securities reiterated a Buy rating on Savara Inc (SVRA), with a price target of $25. The company’s shares closed on Friday at $7.53.

According to, Bayko is a 5-star analyst with an average return of 15.6% and a 45.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Enanta Pharmaceuticals, and Aimmune Therapeutics.

Currently, the analyst consensus on Savara Inc is a Moderate Buy with an average price target of $16.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.06 and a one-year low of $6.21. Currently, Savara Inc has an average volume of 185.9K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SVRA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.